Search

Cyltezo®, First Interchangeable Biosimilar to Humira®, Receives Preferred Formulary Status with Optum Rx for Commercially Insured Patients

KDIGO’s 2024 Updated Guidelines Re-Emphasize Commitment to Comprehensive Testing for CKD

Mohamed Eid shares his thoughts on the updated KDIGO clinical practice guidelines, published in 2024, and the need for guidelines-directed care for CKD.

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

FDA Grants Priority Review for Spesolimab | BI US

Read more about Spesolimab, which has been approved by the FDA as a treatment option for generalized pustular psoriasis (GPP) flares in adults.

Our Curiosity Never Stops | Boehringer Ingelheim US

Hear from Dr. Cornelia Dorner-Ciossek on how brain research informs treatment methods for patients suffering with mental illnesses.

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US

FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.

BI Presents Combination Data of Tiotropium + Olodaterol | Boehringer Ingelheim US

BI presented the first data from the pivotal Phase III TONADO™ 1&2 studies for the FDC of tiotropium plus olodaterol delivered via the Respimat® inhaler.

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

NASH

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Generalized pustular psoriasis (GPP): Unmet needs, the reality of living with the condition, and future management

Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

FDA Approves Boehringer Ingelheim’s STIOLTO™ RESPIMAT® Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Ridgefield, CT | BI Facilities

BI was established in Connecticut in 1971 and broke ground on September 1st, 1989 in Ridgefield. This site is home to the U.S. HQ of Boehringer Ingelheim

Our goal of transforming DLL3-positive carcinomas

Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Chronic Kidney Disease

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers